CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CAR-T 细胞疗法：有效治疗小细胞肺癌的挑战与机遇
英文原题：CAR-T cell therapy: Challenge and opportunity for effective treatment of small cell lung cancer.
查看英文原题
CAR-T cell therapy: Challenge and opportunity for effective treatment of small cell lung cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
小细胞肺癌（SCLC）是一种恶性程度极高的肿瘤，具有快速转移、耐药和频繁复发的特点。由于现有治疗选择有限，其预后仍然较差。近年来，免疫检查点抑制剂联合化疗使治疗应答得到一定改善。本综述阐述SCLC的生物学特征，并概述当前治疗的障碍，包括抗原呈递受损和T细胞浸润不足等；嵌合抗原受体（CAR）T细胞疗法有望克服这些障碍。本文首次汇总现有数据，并讨论CAR-T 细胞疗法治疗SCLC的未来前景。鉴于SCLC具有高度异质性和免疫抑制性肿瘤微环境，可能需要对CAR-T 细胞进行结构改造并采用联合治疗，才能诱导有效的抗肿瘤应答。仍需进一步研究，包括开展临床试验，以确定CAR-T 细胞疗法是否适用于SCLC治疗。
展开英文摘要原文
Small cell lung cancer (SCLC) is a devastating malignancy characterized by rapid metastasis, drug resistance, and frequent recurrence. Owing to the paucity of existing therapeutic options, the prognosis of SCLC remains poor. Recently, the combination of immune checkpoint inhibitors and chemotherapy has resulted in modest improvements in treatment responses. In this review, we characterize the biological signature of SCLC and outline the obstacles to current treatment, including impaired antigen presentation and T cell infiltration.
These obstacles may potentially be overcome by chimeric antigen receptor (CAR)-T cell therapy. For the first time, we summarize the available data and discuss the future prospects of CAR-T cell therapy for the treatment of SCLC. Given the high heterogeneity and immunosuppressive tumor microenvironment of SCLC, structural modifications of CAR-T cells and combination therapy may be required to elicit a successful antitumor response.
Further research, including clinical trials, is needed to determine the suitability of CAR-T cell therapy as a treatment for SCLC.
论文信息
- 作者
- Yin L、Sun P、Guo S、Shuai P、Zhang J
- 第一作者单位
- Department of Health Management Center & Institute of Health Management, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China.China
- 通讯作者单位
- Department of Health Management Center & Institute of Health Management, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, China. Electronic address: zhangjunlin_hx@163.com.China
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Biochimica et biophysica acta. Reviews on cancer2024 Nov
- 原文标识
- PubMed 39615863 · DOI 10.1016/j.bbcan.2024.189228